• AbbVie Strikes Deal for I-Mab Drug With a Potential Edge in CD47 Chase

    23 days ago - By Xconomy

    The cancer protein CD47 is a hot target for drug developers, but it's not without issues. Antibody drugs that block this protein can also spark anemia. I-Mab designed its antibody to pose less of an anemia risk and AbbVie, seeing an opportunity to catch up to other CD47 contenders and potentially stand apart from them, has agreed to pay $200 million to secure rights to the compound. The I-Mab drug, lemzoparlimab, is currently in early clinical development. The $200 million that AbbVie is paying Shangahi-based I-Mab breaks down to $180 million up...
    Read more ...

     

  • Fluorescent glycan nanoparticle-based FACS assays for the identification of genuine drug-resistant cancer cells with differentiation potential

    Fluorescent glycan nanoparticle-based FACS assays for the identification of genuine drug-resistant cancer cells with differentiation potential

    23 days ago - By Springer

    Abstract
    Herein we develop a unique differentiated-uptake strategy capable of efficient and high-purity isolation of genuine drug-resistant cells from three types of drug-surviving cancer cells, which include paclitaxel-surviving human ovarian OVCAR-3 cancer cells and human lung carcinoma A549/Taxol cells, and doxorubicin-surviving human immortalized myelogenous leukemia K562/ADR cells. By using this strategy which relies on fluorescent glycan nanoparticle -based fluorescence-activated cell sorting assays, two subpopulations with distinct fluorescences existing in drug-surviving OVCAR-3...
    Read more ...